Arcus Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
About Arcus Biosciences
Pharmaceutical Preparations, SIC 2834
Arcus is a clinical-stage biopharmaceutical company that develops small-molecule therapies and antibodies for patients with cancer and autoimmune or inflammatory diseases. Its primary oncology pipeline includes casdatifan, an oral HIF-2α inhibitor for kidney cancer; quemliclustat, a CD73 enzyme inhibitor for pancreatic cancer; domvanalimab, an anti-TIGIT antibody for lung cancer; and zimberelimab, an anti-PD-1 antibody. The company also pursues preclinical research targeting inflammatory conditions such as chronic urticaria and atopic dermatitis. Its end users are individuals with these oncologic and inflammatory disorders.
Regarding scale and geography, the company maintains a worldwide patent estate containing more than 850 granted or pending patents, including 41 issued United States patents. Its clinical evaluations span multi-regional trials, with zimberelimab tested in over 2,600 patients. Commercialization and licensing agreements cover global territories, including the United States, alongside Japan and other Asian markets excluding China. The business does not operate internal manufacturing or storage facilities, relying instead on third-party contract manufacturers. Its corporate headquarters location is not stated in the text.
Summary of the business section of Arcus Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arcus Biosciences, Inc.
- Founded
- 2015
- Headquarters
- Hayward, CA
- Address
- 3928 Point Eden Way 94545
- Phone
- (510) 694-6200
- Website
- arcusbio.com
- Employees
- 601, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young, LLP, San Mateo, California
Stock & identifiers
- Ticker
- RCUS
- Exchange
- NYSE
- IPO date
- Mar 16, 2018
- Shares outstanding
- 127M, Jul 30, 2026
- Public float
- $565.88M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1724521
- CUSIP
- 03969F109
- ISIN
- US03969F1093
- LEI
- 213800CSKAC96ELS4K25
- EIN
- 47-3898435
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Terry J. Rosen | Chief Executive Officer, Director | 5,670,279 |
| Alexander Azoy | Chief Accounting Officer | 39,581 |
| Juan C. Jaen | President | 1,200,799 |
| Carolyn C. Tang | General Counsel | 184,607 |
| II Robert C. Goeltz | Chief Financial Officer | 84,161 |
| Richard Markus | Chief Medical Officer | 89,647 |
| Jennifer Jarrett | Chief Operating Officer | 224,024 |
| Dimitry SA Nuyten | Chief Medical Officer | 87,518 |
| Patrick Machado | Director | 44,300 |
| Nicole Lambert | Director | 43,000 |
| Antoni Ribas | Director | 52,853 |
| David L. Lacey | Director | 76,652 |
| Andrew J. Perlman | Director | 48,325 |
| Kathryn E. Falberg | Director | 176,406 |
| Yasunori Kaneko | Director | 957,955 |
| Dietmar Berger | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Rosen | $9.66M | $17.73M | $3.55M | $90 | $88 |
| FY2024 Dr. Rosen | $7.28M | $4.80M | $2.79M | $147 | $95 |
| FY2023 Dr. Rosen | $10.12M | $7.48M | $4.19M | $194 | $94 |
| FY2022 Dr. Rosen | $9.05M | -$2.07M | $4.19M | $205 | $88 |
| FY2021 Dr. Rosen | $9.48M | $14.58M | $5.94M | $401 | $118 |
| FY2020 Dr. Rosen | $5.69M | $12.02M | $5.36M | $257 | $148 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 601 full-time employees, approximately 49% of whom hold Ph.D., M.D., R.N., or similar degrees and certifications.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 19, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 16, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 9, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |